Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Millipore Acquires Remaining Ownership of Joint Venture in India

By LabMedica International staff writers
Posted on 01 Dec 2009
Millipore Corp. More...
(Billerica, MA, USA) has acquired the remaining 60% ownership of its joint venture in India, Millipore India Pvt., Ltd. The transaction will accelerate strategic growth initiatives in India's thriving life science market.

Based in Bangalore, Millipore India is primarily a sales, service, and manufacturing organization that has additional offices in Ahmedabad, Hyderabad, Kolkata, Mumbai, and Delhi. The joint venture's revenues are split evenly between Millipore's Bioprocess and Bioscience divisions.

The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India's thriving life-science market. India represents a critical part of the company's strategy to increase its growth by expanding its presence in BRICS (Brazil, Russia, India, China, and Singapore) countries.

There are more than 80 plants in India approved by the United States Food and Drug Administration (FDA; Silver Spring, MD, USA) to manufacture drugs, and the country accounts for almost 25% of the global generic drug market. In addition, the Indian government has invested US$1.7 billion to expand the country's life science and biotechnology industries and several Indian companies have emerged as global competitors in the biopharmaceutical industry.

"India has experienced unprecedented levels of investment and expansion in the country's biotechnology, pharmaceutical, and life science research industries,” said Martin Madaus, chairman & CEO of Millipore. "By establishing direct operations in the country, we will be able to more effectively execute our strategy and leverage our unique capabilities to accelerate growth and support our growing customer base in this dynamic market.”

Related Links:

Millipore
United States Food and Drug Administration




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.